Spain
Oncomatryx Biopharma is a biopharmaceutical company founded in 2009 and headquartered in Spain. Specializing in the tumor microenvironment, the company has developed precision drugs and diagnostic devices targeting the tumor stroma, including Antibody-Drug Conjugates (ADCs) and human-derived proteins that focus on peritumoral fibroblasts, endothelial cells, and extracellular matrix. These entities play a crucial role in promoting tumor invasiveness, drug resistance, and immunosuppression.
Oncomatryx's innovative approach involves the development of ADCs with proprietary payloads and linker derivatives, demonstrating an optimal therapeutic index against pancreatic cancer in vivo. Notably, their product OMTX705, an ADC targeting cancer-associated fibroblasts (CAFs), has shown promising results in inhibiting pancreatic tumor growth in patient-derived xenograft mice, both as a single agent and in combination with chemotherapy.
The company recently secured a significant €15.00M Venture Round investment on 19 April 2022. Although the specific investors were not disclosed, this investment is anticipated to further fuel Oncomatryx's advancements in biopharma, biotechnology, and healthcare while strengthening its position in the market.
Iksuda Therapeutics